1. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...
  2. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 04

    Reduction of harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    D’RUIZ C.D.(1); O’CONNELL G.(2); GRAFF D.W.(3)
    (1) Scientific Affairs Consultant, Fontem Ventures, B.V., Greensboro, NC, U.S.A.; (2) Fontem Ventures, B.V., Scientific and Regulatory Affairs, Amsterdam, The Netherlands; (3) Celerion, Lincoln, NE, U.S.A.
    Changes in fifteen urine, blood, and exhaled breath biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs), representing major classes of compounds reported by the FDA to be significant contributors to smoking-associated ...
  3. TSRC, Tob. Sci. Res. Conf., 2016, 70, abstr. 23

    Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    O’CONNELL G.(1); GRAFF D.W.(2); D’RUIZ C.(3)
    (1) Fontem Ventures B.V, Amsterdam, The Netherlands; (2) Celerion Inc, Lincoln, NE, USA; (3) Fontem Ventures B.V Greensboro, NC, USA
    Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following randomization ...